Novartis temporarily pausing screening, randomization and treatment across rapcabtagene autoleucel trials in autoimmune diseases
Novartis is temporarily pausing screening, randomization and treatment across all trials of its CAR-T therapy rapcabtagene autoleucel in autoimmune diseases.
News sentiment50 · Neutral
Market impact60/100
Event statedeveloping
The headline is open. The market meaning goes deeper.
Preview the analysis BORSA members receive around every material canonical event.
BORSAPLUSUnlock the intelligence behind the signal.
Create free account · 3 views/day